<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956809</url>
  </required_header>
  <id_info>
    <org_study_id>848538</org_study_id>
    <nct_id>NCT04956809</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure</brief_title>
  <official_title>Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves&#xD;
      submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM&#xD;
      OxPhos) in patients with heart failure and reduced left ventricular ejection fraction&#xD;
      (HFrEF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the change in submaximal exercise endurance (time to exhaustion at 75% of peak workload) between Dapa and placebo.</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>HFrEF</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active arm will be 6 weeks in duration, separated by a 2-week wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm will be 6 weeks in duration, separated by a 2-week wash-out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Tab</intervention_name>
    <description>This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.</description>
    <arm_group_label>Dapagliflozin 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of HFrEF with NYHA Class II-III functional class, which has been present for&#xD;
             at least two months&#xD;
&#xD;
          2. Left ventricular ejection fraction ≤ 40%&#xD;
&#xD;
          3. Stable medical therapy for at least 1 month&#xD;
&#xD;
          4. Plasma NT-proBNP level of: ≥ 200pg/mL; OR ≥ 125pg/mL if they were hospitalized for HF&#xD;
             within the past 12 months; or ≥ 250 pg/mL if patient had atrial fibrillation/flutter&#xD;
             on baseline ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrollment or&#xD;
             previous intolerance of an SGLT2 inhibitor&#xD;
&#xD;
          2. Type 1 diabetes mellitus&#xD;
&#xD;
          3. Age &lt;18 years old&#xD;
&#xD;
          4. Pregnancy: Women of childbearing potential will undergo a urine pregnancy test during&#xD;
             the screening visit.&#xD;
&#xD;
          5. Uncontrolled atrial fibrillation, as defined by a resting heart rate &gt; 100 beats per&#xD;
             minute at the time of the baseline assessment&#xD;
&#xD;
          6. Paroxysmal atrial fibrillation (Afib) or flutter with &gt;1 hour of continuous Afib&#xD;
             documented within the previous 6 months (prior to screening or randomization),&#xD;
             direct-current (DC) cardioversion or ablation procedure for Afib within 6 months, or&#xD;
             plan to attempt to restore sinus rhythm (with drug therapy, ablation, or DC&#xD;
             cardioversion) within 6 months of randomization. Subjects with persistent Afib and no&#xD;
             sinus rhythm documented in the prior 6 months are permitted.&#xD;
&#xD;
          7. Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          8. eGFR &lt; 25 mL/min/1.73m^2, or unstable or rapidly progressing renal disease at the time&#xD;
             of randomization&#xD;
&#xD;
          9. Subject inability/unwillingness to exercise&#xD;
&#xD;
         10. Greater than moderate left sided valvular disease (mitral regurgitation, aortic&#xD;
             stenosis, aortic regurgitation), moderate or greater mitral stenosis, severe&#xD;
             right-sided valvular disease&#xD;
&#xD;
         11. Known hypertrophic, infiltrative, restrictive or inflammatory cardiomyopathy&#xD;
&#xD;
         12. Clinically significant pericardial disease, as per investigator judgment&#xD;
&#xD;
         13. Current angina due to clinically significant epicardial coronary disease, as per&#xD;
             investigator judgment&#xD;
&#xD;
         14. Acute coronary syndrome or coronary intervention within the past 2 months&#xD;
&#xD;
         15. Primary pulmonary artery hypertension (WHO Group 1 Pulmonary Arterial Hypertension)&#xD;
&#xD;
         16. Clinically significant lung disease as defined by: Chronic Obstructive Pulmonary&#xD;
             Disease meeting Stage III or greater GOLD criteria (FEV1&lt;50% predicted), treatment&#xD;
             with oral steroids within the past 6 months for an exacerbation of obstructive lung&#xD;
             disease, current use of supplemental oxygen aside from nocturnal oxygen for the&#xD;
             treatment of obstructive sleep apnea.&#xD;
&#xD;
             - Desaturation to &lt;90% on the baseline maximal effort cardiopulmonary exercise test&#xD;
             will also be grounds for exclusion&#xD;
&#xD;
         17. Clinically-significant ischemia, as per investigator's judgement, on stress testing&#xD;
             without either (1) subsequent revascularization, (2) an angiogram demonstrating the&#xD;
             absence of clinically significant epicardial coronary artery disease, as per&#xD;
             investigator judgment; (3) a follow-up 'negative' stress test, particularly when using&#xD;
             a more specific technique (i.e., a negative perfusion imaging test following a&#xD;
             'positive' ECG stress test)&#xD;
&#xD;
             - Exercise induced regional wall motion abnormalities suggestive of ongoing ischemia&#xD;
             during the baseline maximal effort cardiopulmonary exercise test will be exclusionary&#xD;
&#xD;
         18. Implantation of a CRT device within 12 weeks prior to enrollment or intent to implant&#xD;
             a CRT device during the study period&#xD;
&#xD;
         19. Previous cardiac transplantation or implantation of a ventricular assist device, or&#xD;
             implantation expected after randomization&#xD;
&#xD;
         20. Symptomatic bradycardia or second- or third-degree heart block, in the absence of a&#xD;
             pacemaker&#xD;
&#xD;
         21. Significant liver disease impacting synthetic function or volume control (ALT/AST &gt; 3x&#xD;
             ULN, Albumin &lt; 3.0 g/dL)&#xD;
&#xD;
         22. Severe right ventricular dysfunction&#xD;
&#xD;
         23. Baseline resting seated systolic blood pressure &gt; 180 mmHg or &lt;90 mmHg&#xD;
&#xD;
         24. Orthostatic blood pressure response to the transition from supine to standing (&gt;20&#xD;
             mmHg reduction in systolic blood pressure 2-3 minutes after standing)&#xD;
&#xD;
         25. Active participation in another study that utilizes an investigational agent&#xD;
             (observational studies/registries allowed)&#xD;
&#xD;
         26. Any condition that, in the opinion of the investigator, will interfere with the&#xD;
             completion of the study. This may include comorbid or psychiatric conditions that may&#xD;
             impede successful completion of the protocol, or logistical concerns (e.g. inability&#xD;
             to travel to the exercise unit).&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kimberly clinton</last_name>
      <phone>215-662-2803</phone>
      <email>kimberly.clinton@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Margulies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kenneth B Margulies</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

